Updated hospital associated venous thromboembolism outcomes with 90-days follow-up after hospitalisation for severe COVID-19 in two UK critical care units

Andrew J. Doyle(St Thomas' Hospital), Beverley J. Hunt, Karen Breen(University College London Hospitals NHS Foundation Trust), Andrew Retter(St Thomas' Hospital), Will Thomas(Cambridge University Hospitals NHS Foundation Trust), Stephen MacDonald(Cambridge University Hospitals NHS Foundation Trust), Martin Besser(Cambridge University Hospitals NHS Foundation Trust), Michael Desborough(Guy's and St Thomas' NHS Foundation Trust)
Thrombosis Research
October 8, 2020
10.1016/j.thromres.2020.10.007
Cited by 12

Related Papers

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up
|Journal of the American College of Cardiology|2020|2.9k
Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies
|British Journal of Haematology|2012|861
Editor's Choice – European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis
|European Journal of Vascular and Endovascular Surgery|2020|709
A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura
|Blood|2011|420
Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial
|The Lancet Haematology|2016|404